Ready to use technologies and their role in lean biomanufacturing

168 | P a g e DOI: 10.5281/zenodo.17359056 Ready to use technologies and their role in lean biomanufacturing Dharmasoth Rama Devi1*, Sanapala Usha Rani2, Nadimpalli Vineela3, Nooka Gouri Sankar4, Gondela Alekhya5, Keloth Basavaiah6 1, 2,3,4,5 (Department of Pharmacognosy, Vignan Institute of Pharmaceutical Technology, Duvvada, Visakhapatnam, Andhra Pradesh, India) 6 (Department of chemistry, Andhra University, Visakhapatnam, Andhra Pradesh, India) Corresponding author Dharmasoth Rama Devi [email protected] Abstract The lean biomanufacturing industry, seeks lean management, processes to minimize waste, improve efficiency, and optimize production processes. Ready-to-use technologies, like single-use systems, consumables, and sterilized equipment have significant advantages over reusable systems. RTU solutions are pre-prepared, prevalidated, and immediately available for use, eliminating the need for additional preparation, cleaning, sterilization, testing, and validation. Accelerates process setup and turnaround times, allowing manufacturers to respond swiftly to changing production demands where rapid adaptation to new products or process changes is often required. With the rapidly advancing field of biomanufacturing, the adoption of ready-to-use technologies is revolutionizing the landscape of lean biomanufacturing, enabling businesses to enhance their operations, reduce production expenses, minimize the risk of contamination, elevate product quality, improve regulatory compliance, and lower their overall competitiveness. Ready-to-use technologies also contribute to sustainability by decreasing energy, water, and chemical consumption typically associated with cleaning and sterilization. Introducing these ready-to-use technologies into manufacturing operations enables more efficient, faster, and more reliable operations, enabling companies to focus on quality, innovation, and customer satisfaction. This chapter explores the role of ready-to-use technologies, including single-use systems, modular production units, digital transformation, sustainability, green chemistry, and the function of regulatory agencies in current systems. Keywords: Ready-to-use technology, single use systems, modular processes, waste reduction, biomanufacturing, biologics. 1. Introduction Biomanufacturing Biomanufacturing involves the use of biological systems or organisms to produce various 169 | P a g e DOI: 10.5281/zenodo.17359056 goods, especially biopharmaceuticals and biologics [1]. This sector is essential to both healthcare and biotechnology, employing living cells or their parts to create products crucial for medical treatment, diagnosis, and the prevention of diseases. The biomanufacturing process includes many methods that utilize microorganisms, plant cells, or animal cells in controlled settings to manufacture therapeutic agents, vaccines, enzymes, and other products. Biomanufacturing integrates several disciplines, such as molecular biology, material science, chemical engineering and biochemistry. The steps involved may encompass cell cultivation, fermentation, purification, and formulation. A fundamental aspect of biomanufacturing is the cultivation of cells in optimal conditions. Advances in the cell culture techniques leads to improved yield, efficiency, and enhanced quality of biopharmaceuticals [2]. The selection of cell types may be mammalian, microbial, or plant depends on the target product. Fermentation process utilizes microorganisms to convert raw materials into desired end products. The fermentation process may differ greatly based on temperature, pH, and nutrient availability [3]. After production, biopharmaceutical products require purification and conversion into final dosage forms. Strict quality control procedures are guided by regulatory agencies such as European Medicines Agency (EMA) and the Food and Drug Administration [4]. Which are necessary to ensure uniformity, efficacy, safety and the removal of contaminants because of the biological nature of these products. Biomanufacturing industries adopting lean principles are playing a major role in the production of biologics and biopharmaceuticals. Biologics are associated with complexity and scalability issues. Technologies such as modular manufacturing units, process analytical technologies, and single-use systems enable faster batch transitions and less downtime. This is consistent with Lean approaches, which eliminate non-value-added activities and place an emphasis on value creation [5]. The integration of these technologies ensures higher standards of quality and enhances productivity, reducing waste, streamlining production process. Therefore, implementing Lean principles through these innovations fosters a more adoptable manufacturing environment, enabling businesses to react quickly to shifting market needs and ultimately enhancing patient access to critical therapies. 1.1 Ready-to-Use Technologies Ready-to-use technologies refer to solutions, tools, or systems that can be easily implemented or used with little setup or customization required. These technologies are crafted to be user-friendly and accessible, intended for individuals and organizations that may not possess extensive technical knowledge. Ready-to-use technologies often feature intuitive interfaces and simple installation processes, making them available to a diverse group of users. In contrast to custom solutions, ready-to-use technologies are intended to address the general needs of users, thereby minimizing the necessity for significant modification. By removing the requirement for complex development, users can conserve both time and expenses, making these technologies attractive for small enterprises and startups. Organizations can quickly adopt these technologies, enabling them to react more rapidly to market demands or operational issues. Numerous ready-to-use technologies provide scalable options, permitting businesses to adjust the solutions as they expand without substantial overhauls. Examples of readyto-use technologies include Cloud Computing Services, with platforms like Google Cloud, Microsoft Azure, and AWS offering readily adoptable infrastructure and services. Some of the subscription based models of Software 170 | P a g e DOI: 10.5281/zenodo.17359056 as a Service (SaaS) applications such as Sales force, Slack, and Zoom are created for immediate use with subscription-based models, allowing users to start without significant installations. Many consumer applications, ranging from productivity tools to social media platforms, are designed for quick installation and ease of use. Ready-to-use technologies are transforming numerous sectors, including healthcare, education, and business. They enable healthcare providers rapidly adapt to digital solutions, help educational institutions to offer online learning effortlessly, and assist businesses in optimizing operations without extensive IT support [6-12]. There is an increasing emphasis on sustainable practices in biomanufacturing. This includes using renewable resources, reducing waste, and employing energy-efficient processes. The industry is focused on minimizing its environmental footprint while maintaining product efficacy [13]. Advances in biomanufacturing techniques have also prompted changes in regulatory frameworks. Regulatory agencies are adapting to ensure that quality and safety standards keep pace with innovations, facilitating the approval of new biopharmaceuticals [14]. Regulatory agencies and their role are presented in Table 1. Table 1: Different organizations role in biomanufacturing and lean compliance Agency / Organization Jurisdiction / Scope Role in Biomanufacturing & Lean Compliance Reference US Food and Drug Administration (FDA) – Center for Biologics Evaluation and Research (CBER) United States Regulates biologics—biological therapeutic agents (e.g., vaccines, gene therapies); ensures safety, efficacy, and quality of biomanufacturing. [15] US FDA – Office of Regulatory Affairs (ORA) / Office of Global Regulatory Operations and Policy (GO) United States Enforces federal laws across biologics, drugs, devices, ensuring compliance in biomanufacturing operations. [16] European Medicines Agency (EMA) European Union Central regulator for biopharmaceutical products in EU; shapes harmonized regulatory standards used in lean biomanufacturing strategies. [17] International Council for Harmonisation (ICH) Global (pharma/biolo gics sector) Develops harmonized guidelines (quality, safety, efficacy) widely adopted in lean biomanufacturing to ensure standardized global compliance. [18] World Health Organization (WHO) / Codex Alimentarius Global (guidelines body) Provides global guidelines and standards influencing national biotech and biomanufacturing regulations. [19] Environmental Protection Agency (EPA) / US Department of Agriculture (USDA) United States Collaborated with FDA to create a unified regulatory plan for biotechnology, covering areas like modified organisms and biologics. [20] National Biosafety Management Agency (NBMA) Nigeria Regulates modern biotechnology activities—including biomanufacturing— to safeguard public health and the environment. [21] 1.1.1 Role of Ready-to-Use Technologies in Lean Biomanufacturing The adoption of ready-to-use technologies in lean biomanufacturing involves increasing productivity by 171 | P a g e DOI: 10.5281/zenodo.17359056 streamlining the process and reducing manual labour, enhancing flexibility by rapid scale-up or scale-down of production, and reducing costs. Pre-sterilized, single-use bioreactors and bags simplify operations and reduce cleaning and validation [22-25].Ready to use technology like modular bioreactors were provided by GE Healthcare’s Xcellerate company with set parameters, enabling manufacturers to uphold consistent practices without requiring complex setups. Standardized, pre-sterilized containers (BPCs) supplied by Thermo Fisher Scientific company that lowers the risk of contamination and also ensures uniform handling of cell cultures, which enhances batch reproducibility. Merk KGaA’s solutions provided standardized , pre-assembled components that help during upstream cell culture and downstream purification processes. Standardized Quality Management Systems (QMS) are implemented using software like Veva Vault, which helps create consistent Standard Operating Procedures (SOPs) and documentation. Standardized control systems like those from ATS ensure consistent monitoring and adjustments during production, improving reproducibility; standardization lessens human error and process variability, guarantees higher-quality biologics, and simplifies regulatory approval procedures. Standardized control systems like those from ATS ensure consistent monitoring and adjustments during production, improving reproducibility; standardization lessens human error and process variability, guarantees higher-quality biologics, and simplifies regulatory approval procedures. Figure 1: Role of ready-to-use technologies in lean biomanufacturing 1.1.2 Examples of RTU Technologies [26] • RTU Vials and Syringes(e.g., SCHOTT, West, BD) • Sterile Tubing Sets and Connectors(e.g., CPC AseptiQuik®, Pall Kleenpak®) • RTU Single-use Bioreactors(e.g., Sartorius BIOSTAT®, ThermoHyPerforma®) 172 | P a g e DOI: 10.5281/zenodo.17359056 • Presterilized Filter Capsules (e.g., Millipore, Pall) 1.2 Single-Use Systems [27-28] Single-use systems are disposable devices and materials used in biomanufacturing processes, which removes the requirement for sterilization and cleaning associated with traditional reusable systems. These systems greatly enhance operational efficiency and reduce turnaround times, closely aligning with lean methodologies that focus on minimizing waste and maximizing process efficiency. SUTs facilitate rapid facility setup, scalable production, and effective contamination control. They are essential for the production of biologics, vaccines, and gene/cell therapies, as well as for modular and mobile manufacturing. They have been extensively adopted in both clinical and commercial environments by leading pharmaceutical and biotech companies. Case studies and applications of single –use technologies presented in Table 2. Table: 2 Case Study and Applications of Single-Use Technologies (SUTs) S.No Company/Organ ization Application Technology Used Key Outcomes References 1. Genentech(Roche Group) Monoclonal antibody production (2,000 L scale) Wave bioreactors, single-use bags, mixers 60% reduction in changeover time; decreased cleaning and validation costs [29] 2. Merck & Co. Pandemic vaccine manufacturing (Influenza) SU fermenters, depth filters, tubing Facility ready in <12 months; enabled rapid pandemic response [30] 3. Samsung Biologics Contract manufacturing for biosimilars Disposable chromatography columns, SU mixers Enhanced flexibility and capacity; multiproduct capabilities [31] 4. Oxford Biomedica (UK) Lentiviral vector production for gene therapy SU fixed-bed bioreactors, sensors Reduced contamination risks; GMP compliance for cell therapy [32] 5. Cytiva (GE Healthcare) Modular biomanufacturing facilities (KUBio™) Pre-fabricated cleanrooms, SU bioprocessing units Deployment in <18 months; scalable, mobile GMP facility [33] 6. CAR-T Cell Therapy Facilities (e.g., Novartis, Kite) Patient-specific autologous cell therapies Closed-loop SU tubing and cell culture sets High aseptic assurance; batchspecific flexibility [34] 1.3 Modular Process Designs Modular systems consist of integrating various modular units, such as bioreactors, chromatography systems, and downstream processing modules, into a unified workflow. While each module operates autonomously, they connect seamlessly with one another to form a fully functional system. Modules are designed using standardized specifications and protocols, which enhances their interchangeability 173 | P a g e DOI: 10.5281/zenodo.17359056 [35]. The modular design offers flexible scaling, permitting adaptations from small to large production volumes without major redesign efforts [36]. New modules can be incorporated into existing systems without interrupting current operations, thereby fostering innovation and adaptability to new technologies. The effective implementation of modular process designs necessitates thorough planning and execution, including: assessing specific production requirements and desired results, which dictate the necessary types and arrangements of modules. Engineering teams are tasked with developing and producing modules that comply with established industry benchmarks while ensuring compatibility with the current systems [37]. Prior to largescale implementation, it is essential to conduct pilot testing of modular components to assess their performance and identify possible integration challenges. Personnel must be equipped with the knowledge to operate and optimize modular systems, making sure that the entire team recognizes the modular concept and its advantages [38-39]. The modular approach allows for ongoing monitoring and control of individual components, ensuring that any quality standard deviations can be promptly addressed [40]. Standardizing components reduces variability, fostering consistency in product quality through predictable performance across all modules [41]. Additionally, modular systems can be structured to include compliance features directly, making it easier to achieve regulatory compliance and simplifying validation procedures [42]. 1.4 Automation in Biomanufacturing Automation in biomanufacturing involves a range of technologies aimed at improving production effectiveness, accuracy, and maintaining a high level of quality in the biopharmaceutical manufacturing process. Recognizing the different categories of automation, such as Process Automation, Lab Automation, Data Acquisition and Process Control Systems, Robotics and Artificial Intelligence, and Supply Chain Automation, can assist organizations in choosing the right systems that fit their operational objectives. Process automation uses both software and hardware solutions to autonomously manage biomanufacturing processes, thus minimizing human involvement. Examples of process automation technologies like automated bioreactors, fermentation systems, and downstream purification systems strictly uphold process parameters, guaranteeing consistency in product results. Lab automation improves laboratory functions through robotic technologies and automated instruments that carry out repetitive tasks. Systems such as high-throughput screening, liquid handling mechanisms, and automated analytical devices enhance experimental workflows while reducing both turnaround times and labor expenses [43]. These systems gather and analyze data from different production stages, offering real-time updates on product quality and process performance. Supervisory control and data acquisition (SCADA) systems, distributed control systems (DCS), and process analytical technologies (PAT) allow manufacturers to track critical quality attributes and enhance production settings. Robotics and AI concentrate on automating intricate tasks and decision-making processes. Robotic arms execute high-precision activities like aseptic filling and packaging, while AI algorithms sift through large datasets to improve predictive maintenance and boost operational efficiency. This technology optimizes supply chain functions, guaranteeing that raw materials and components are available on time. Automated inventory management systems and predictive analytics enhance supply chain agility, further supporting lean manufacturing ideals by reducing waste and maximizing resource use. [44]. 174 | P a g e DOI: 10.5281/zenodo.17359056 1.5 Best Practices for Seamless Integration A comprehensive Planning detailing the integration process, timelines, resource allocation, and stakeholder roles is fundamental to successful implementation. This plan should delineate clear goals aligned with lean principles to ensure that waste is minimized throughout the integration process [45]. Engaging stakeholders from various departments—such as quality assurance, production, and IT—early on can provide invaluable insights. This collaboration ensures that the chosen technologies address the specific needs and concerns of all parties involved [46]. Pilot testing is crucial before full-scale implementation. This process allows organizations to identify potential integration issues and gather user feedback for improvements. By establishing a testing framework that aligns with regulatory standards, biomanufacturers can ensure compliance and operational efficacy (FDA, 2022). Post-integration, organizations should implement robust monitoring mechanisms to evaluate the performance of the new technology. Continual assessment helps identify areas for improvement and allows organizations to adapt to changing regulatory requirements and market demands. Effective documentation of the integration process aids in troubleshooting future issues. Keeping records of the challenges faced, solutions implemented, and user feedback creates a valuable knowledge base that fosters learning and improvement within the organization [47]. 1.6 Quality and Regulatory Considerations In the field of biomanufacturing, it is essential to adhere to quality and regulatory guidelines to guarantee the safety, effectiveness, and trustworthiness of biopharmaceutical products. Compliance involves a broad spectrum of regulations established by organizations such as the FDA (Food and Drug Administration), EMA (European Medicines Agency), and ICH (International Council for Harmonisation). These regulations specify the processes and systems that companies must adopt to uphold product integrity and ensure patient safety throughout the manufacturing process [48]. To achieve compliance, businesses can incorporate ready-to-use technologies like automated quality management systems (QMS) and electronic laboratory notebooks (ELN). These technologies support the standardization of processes, enable real-time data collection, and ease documentation, which is critical for fulfilling regulatory requirements. For example, the implementation of integrated quality systems can enhance workflows and reduce human error—both crucial factors that regulatory agencies examine during compliance assessments [49]. Another key element of quality assurance in biomanufacturing is risk management. By utilizing systematic risk assessment methods, organizations can proactively pinpoint, assess, and minimize potential risks throughout the production process. The integration of ready-to-use technologies strengthens risk management by offering solid analytics and predictive modeling features. For instance, software applications that leverage artificial intelligence can anticipate potential failures and recommend corrective measures before they affect product quality [50]. A crucial component of risk management is the adoption of a Quality by Design (QbD) strategy, which focuses on developing manufacturing processes to ensure quality results. By employing ready-to-use technologies, companies can simulate various production scenarios and their related risks, leading to better-informed decision- 175 | P a g e DOI: 10.5281/zenodo.17359056 making. This approach not only helps in meeting regulatory obligations but also enhances operational efficiency and cost-effectiveness [51]. 1.7 Future Perspectives in Biomanufacturing The biomanufacturing industry is experiencing rapid transformation, largely driven by innovations in technology and scientific research. Current trends indicate that ready-to-use technologies will play a crucial role in enhancing the efficiency and scalability of production processes. One notable innovation is the implementation of continuous biomanufacturing, which facilitates the seamless production of biopharmaceuticals in contrast to conventional batch processes. This approach not only lowers production expenses but also improves the consistency and quality of the product [52]. Another promising development is the combination of synthetic biology with the biomanufacturing. Ready-to-use platforms that enable the rapid design, build, test, and learn (DBTL) cycle help create novel microorganisms engineered for specific production goals. Through the use of automated gene editing and optimization systems, companies can greatly reduce the time needed to introduce new therapeutics to the market [53]. In the area of bioprocessing, the progress of artificial intelligence and machine learning are paving the way for smarter production environments.These technologies have the ability to analyze extensive data in real-time, offering insights that enables proactive modifications in manufacturing processes. This capability results in enhanced yields and a reduction in downtime, allowing companies to respond quickly to market demands [54]. 1.8 The Role of Digital Transformation The integration of ready-to-use technologies such as the Internet of Things (IoT), big data analytics, cloud computing is revolutionizing the biomanufacturing industry. Through IoT-enabled equipment, data from different stages can be collected and analysed in real-time, facilitating greater transparency and enabling predictive maintenance [55].Cloud-based solutions offer scalable infrastructure for the storage of data and analysis, making it easier for companies to collaborate and share insights across global market where biomanufacturers need to coordinate their supply chains effectively [56]. Furthermore, the implementation of digital twin technology allows for the creation of virtual representations and identifies inefficiencies without disrupting actual operations. As digital strategies become increasingly integrated into biomanufacturing, they will further promote the use of lean principles. Through the use of real-time data and sophisticated analytics, companies can perpetually enhance and streamline their processes, thus maximizing value while reducing waste and inefficiencies [57]. 1.8 Conclusion Ready-to-use technologies play a vital role in lean biomanufacturing enabling companies to streamline processes, reduce waste and improve efficiency. By adopting these technologies, biomanufacturers can achieve faster turnaround times and greater flexibility in responding to change in production demand. By simplifying operations and ensuring consistent quality. RTU solutions enable facilities to reduce the risk of contamination, improve compliance, and streamline regulatory approval processes. Scalability and modality of RTU systems growth and innovation while maintaining operational efficiency.Integration of digital transformation strategies like IoT, big data analytics, cloud computing supports real-time decision-making, enabling biomanufacturers to 176 | P a g e DOI: 10.5281/zenodo.17359056 consistently optimize their operations. This transformation not only streamlines production but also encourages better teamwork, increases data integrity, and enhances adaptability to regulatory updates. These findings show how technology allows biomanufacturers to strengthen their competitive position. 1.9 Acknowledgements We would like to express sincere gratitude to Y. Srinivasa Rao, Principal, Vignan Institute of Pharmaceutical Technology and Dr.L.Rathaiah, Chairman, Vignan Group of Institutions, for providing the necessary facilities to carry out the work. References [1] J. Conner, D. Wuchterl, M. Lopez, B. Minshall, R. Prusti, D. Boclair, J. Peterson, C. Allen. The biomanufacturing of biotechnology products. In Biotechnology Entrepreneurship, 1, 2014, 351. [2] A. Aijaz, M. Li, D. Smith, D. Khong, C. LeBlon, O. S. Fenton, R. M. Olabisi, S. Libutti, J. Tischfield, M. V. Maus, R. Deans. Biomanufacturing for clinically advanced cell therapies. Nature Biomedical Engineering, 2(6), 2018, 362. [3] S. Manpreet, S. Sawraj, D. Sachin, S. Pankaj, U. C. Banerjee. Influence of process parameters on the production of metabolites in solid-state fermentation. Malaysian Journal of Microbiology, 2(1), 2005, 1. [4] T. Garcia, J. Bergum, J. Prescott, R. Tejwani, T. Parks, J. Clark, W. Brown, F. Muzzio, S. Patel, C. Hoiberg. Recommendations for the assessment of blend and content uniformity: modifications to withdrawn FDA draft stratified sampling guidance. Journal of Pharmaceutical Innovation, 10(1), 2015, 76. [5] R. Ahmad, R. F. Amin, S. A. Mustafa. Value stream mapping with lean thinking model for effective nonvalue added identification, evaluation and solution processes. Operations Management Research, 15(3), 2022, 1490. [6] R. Gohil, H. Patel. Comparative analysis of cloud platform: Amazon Web Service, Microsoft Azure, and Google Cloud Provider: A review. International Conference on Computing Communication and Networking Technologies (ICCCNT), 24, 2024, 1. [7] S. S. Boda. Exploring software as a service security architecture challenges and considerations (Doctoral dissertation, University of the Cumberlands), 2024. [8] C. LeRouge, C. Van Slyke, D. Seale, K. Wright. Baby boomers’ adoption of consumer health technologies: survey on readiness and barriers. Journal of Medical Internet Research, 16(9), 2014, e200. [9] A. Shaqour, S. Salha, Z. Khlaif. Students' characteristics influence readiness to use mobile technology in higher education. Education in the Knowledge Society (EKS), 22, 2021, e23915. [10] A. G. Lopes. Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitations. Food and Bioproducts Processing, 1, 2015, 93. [11] C. El Zant, K. Benfriha, S. Loubère, A. Aoussat, O. A. Adjoul. A design methodology for modular processes orchestration. CIRP Journal of Manufacturing Science and Technology, 1, 2021, 35.